Abstract
In the recent years, integrase (IN) has emerged as an important new target for the development of anti-HIV-1 agents. The enzyme is involved in a key stage of the retroviral replicative cycle, and interacts with a range of cellular co-factors. Due to the absolute necessity of the enzyme for successful infection and the range of cellular cofactors employed by the enzyme, new ways of targeting both IN and its cofactors could yield agents with improved resistance profiles. Allosteric inhibitors are currently receiving a great deal of focus from both academia and industry alike and offer the possibility of a new class of anti-HIV-1 inhibitor.
Keywords: ALLINI, Allosteric, HIV-1, Integrase, LEDGIN, LEDGF/p75, Multimerization, PIC, Retrovirus, STI.
Related Journals
New Emirates Medical Journal
Current Traditional Medicine
Adolescent Psychiatry
Anti-Infective Agents
Current Respiratory Medicine Reviews
Current Psychopharmacology
Endocrine, Metabolic & Immune Disorders - Drug Targets
Current Diabetes Reviews
Infectious Disorders - Drug Targets
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Related Books
Andrology: Current and Future Developments
Male Infertility: An Integrative Manual of Western and Chinese Medicine
Awake Thoracic Surgery
The Anatomical Foundations of Regional Anesthesia and Acute Pain Medicine Macroanatomy Microanatomy Sonoanatomy Functional anatomy
Frontiers in Anti-infective Agents
Frontiers in Anti-infective Agents
Frontiers in Anti-infective Agents
Frontiers in Anti-infective Agents
Frontiers in Anti-infective Agents
Frontiers in Anti-infective Agents